Back to search
FDAFDA · Food and drugs·Recall number D-0178-2024

Doxycycline Capsules, USP 100 mg, 50 Capsules, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 Unite States; Manufactured by: Lupin Limited, Nagpur - 441 108, INDIA. NDC 68180-652-08

Published January 3, 2024 · Recall initiated: January 26, 2022

Summary

FDA records drug Class II recall D-0178-2024, published January 3, 2024 and initiated January 26, 2022. Recalling firm: CARDINAL HEALTHCARE; Status: Terminated; Reported quantity: 1 unit; Lot: Batch G104819. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

What to do

Voluntary: Firm initiated · Letter

Get an email if DOXYCYCLINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DOXYCYCLINE
Manufacturer
CARDINAL HEALTHCARE
Distributor
Nationwide USA
UPC
0368180652083
Lot
Batch G104819
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Doxycycline Capsules, USP 100 mg, 50 Capsules, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 Unite States; Manufactured by: Lupin Limited, Nagpur - 441 108, INDIA. NDC 68180-652-08 recalled?

Yes. FDA published recall D-0178-2024 on January 3, 2024. Reported hazard: CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DOXYCYCLINE. UPC: 0368180652083.